TABLE 1.
Baseline characteristics of the study participants, intervention patients divided into groups based on TOC timing
| Intervention (n = 77) | TOC before treatment decision (n = 11) | TOC after treatment decision (n = 51) | No TOC (n = 12) a | Control (n = 77) | |
|---|---|---|---|---|---|
| Female N (%) | 57 (74.0) | 8 (72.7) | 37 (72.5) | 10 (83.3) | 58 (75.3) |
| Age mean (±SD) | 61.8 (11.4) | 62.4 (8.7) | 61.4 (11.0) | 61.3 (15.6) | 59.3 (12.2) |
| Cancer type N (%) | |||||
| Breast | 38 (49.4) | 6 (54.5) | 24 (47.1) | 8 (66.7) | 40 (51.9) |
| Colorectal | 20 (26.0) | 4 (36.4) | 14 (27.5) | 2 (16.7) | 18 (23.4) |
| Melanoma | 13 (16.9) | ‐ | 9 (17.6) | 2 (16.7) | 11 (14.3) |
| Lung | 3 (3.9) | ‐ | 3 (5.9) | ‐ | 2 (2.6) |
| Gynaecologic | 3 (3.9) | 1 (9.1) | 1 (2.0) | ‐ | 6 (7.8) |
| Hospital setting N (%) | |||||
| Academic | 22 (28.6) | 6 (54.5) | 13 (25.5) | 2 (16.7) | 24 (31.2) |
| Non‐academic | 55 (71.4) | 5 (45.5) | 38 (74.5) | 10 (83.3) | 53 (68.8) |
| Cancer stage b N (%) | |||||
| 0 | 2 (2.6) | ‐ | 2 (3.9) | ‐ | 2 (2.6) |
| I | 34 (44.2) | 4 (36.4) | 21 (41.2) | 7 (58.3) | 34 (44.2) |
| II | 22 (28.6) | 2 (18.2) | 15 (29.4) | 4 (33.3) | 27 (35.1) |
| III | 18 (23.4) | 5 (45.5) | 12 (23.5) | 1 (8.3) | 14 (18.2) |
| IV | 1 (1.3) | ‐ | 1 (2.0) | ‐ | ‐ |
| Education | |||||
| Low | 32 (41.6) | 5 (45.5) | 20 (39.2) | 5 (41.7) | 25 (32.5) |
| Middle | 13 (16.9) | 1 (9.1) | 10 (19.6) | 2 (16.7) | 18 (23.4) |
| High | 32 (41.6) | 5 (45.5) | 21 (41.2) | 5 (41.7) | 34 (44.2) |
| Number of comorbidities (N %) | |||||
| None | 25 (32.5) | 5 (45.5) | 15 (29.4) | 5 (41.7) | 39 (50.6) |
| ≥1 | 52 (67.5) | 6 (54.5) | 36 (70.6) | 7 (58.3) | 38 (49.4) |
| Number of GP contacts (year prior inclusion) median (Q1–Q3) | 7 (4.0–0.0) | 7 (3.0–10.0) | 6 (3.0–9.0) | 8 (6.0–12.3) | 6 (3.5–11.0) |
| Perceived self‐efficacy (PEPPI‐5) mean (±SD) | 21.0 (±3.3) | 21.3 (±2.4) | 21.2(±3.0) | 21.5 (±3.8) | 21.5 (±3.0) |
| GP years of working experience median (Q1–Q3) | 17 (12.0–25.5) | 26 (10.0–34.0) | 16 (12.0–22.0) | 20 (12.3–27.5) | 16 (10.5–24.5) |
| GP setting N (%) | |||||
| Urban c | 51 (66.2) | 7 (63.6) | 36 (70.6) | 6 (50) | 45 (58.4) |
| Between rural and urban d | 14 (18.2) | 1 (9.1) | 9 (17.6) | 3 (25) | 15 (19.5) |
| Rural e | 12 (15.6) | 3 (27.3) | 6 (11.8) | 3 (25) | 17 (22.1) |
Abbreviations: SD, standard deviation; Q1, Interquartile range at 25%; Q3, Interquartile rage at 75%; TOC, Time Out consultation; PEPPI, Perceived Self‐Efficacy in Patient–Physician Interactions.
a
Excluding lost to follow‐up, n = 3.
b
Stage based on clinical TNM classifications.
c
≥1000 addresses per km2.
d
1000–1500 addresses per km2.
e
≤1000 addresses per km2.